Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Extensive and Recalcitrant Alopecia Areata
NCT03800979Phase 4Completed
- Sponsor
- St John's Institute of Dermatology
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib oral solution in alopecia areata, sponsored by St John's Institute of Dermatology. Primary endpoint: Severity of Alopecia Tool Score at 48 weeks. Started Jan 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03800979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800979.